

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10595453	
	Filing Date		2006-04-28	
	First Named Inventor	James W. Larrick		
	Art Unit	1617		
	Examiner Name	Carlos A. Azpuru		
Attorney Docket Number		1953233.00008		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/C.A./	1	20030077312	A1	2003-04-24	Schmulewicz et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/C.A./	1	99/25336	WO	A1	1999-05-27	Lipogenics, Inc.		<input type="checkbox"/>
/C.A./	2	03/039612	WO	A2	2003-05-15	DSB Invest Holding SA		<input type="checkbox"/>
/C.A./	3	03/045582	WO	A1	2003-05-06	Nanomederal Technologies, Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595453
Filing Date	2006-04-28
First Named Inventor	James W. Larrick
Art Unit	1617
Examiner Name	Carlos A. Azpuru
Attorney Docket Number	1953233.00008

/C.A./	4	03/053407	WO	A1	2003-07-03	Research Development Foundation	<input type="checkbox"/>
/C.A./	5	03/072159	WO	A1	2003-09-04	Novartis AG	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
/C.A./	1	BLANN et al. "Free radicals, antioxidants, and endothelial cell damage after percutaneous transluminal coronary angioplasty." Coron Artery Dis. 1993 Oct;4(10):905-10. PubMed PMID: 8269197.	<input type="checkbox"/>
/C.A./	2	DEMAIO et al. "Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA)." J Am Coll Nutr. 1992 Feb;11(1):68-73. (Andreas Gruentzig Cardiovascular Center, Department of Internal Medicine (Cardiology), Atlanta, GA.)	<input type="checkbox"/>
/C.A./	3	DENG et al. "Probucol protects against smooth muscle cell proliferation by upregulating hehe oxygenase-1" Circulation, 2004 Sep 28; 110(13):1855-60. Epub 2004 Sep 13.	<input type="checkbox"/>
/C.A./	4	FERNS et al. "Probucol inhibits neointimal thickening and macrophase accumulation after balloon injury in the cholesterol-fed rabbit." Proc. Natl. Acad. Sci., 89:11312-11316, Dec. 1992.	<input type="checkbox"/>
/C.A./	5	FREYSCHUSS et al. "Antioxidant Treatment Inhibits the Development of Intimal Thickening after Balloon Injury of the Aorta in Hypercholesterolemic Rabbits." J. Clin. Invest., 92:1282-1288, 1993.	<input type="checkbox"/>
/C.A./	6	GODFRIED et al. "Potentiation of atherosclerotic lesions in rabbits by a high dietary level of vitamin E." British Journal of Nutrition, 1989 May;61(3):607-17. Pub Med PMID: 2758015.	<input type="checkbox"/>
/C.A./	7	JIANG et al. "Gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention." Am. J. Clin. Nutr., 2001 Dec;74(6):714-22.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595453
Filing Date	2006-04-28
First Named Inventor	James W. Larrick
Art Unit	1617
Examiner Name	Carlos A. Azpuru
Attorney Docket Number	1953233.00008

/C.A./	8	KONNEH et al. "Vitamin E inhibits the intimal response to balloon catheter injury in the carotid artery of the cholesterol-fed rat." Atherosclerosis. 1995 Feb;113(1):29-39. PubMed PMID: 7755653.	<input type="checkbox"/>
/C.A./	9	LAFONT et al. "Effect of alpha-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis." J. Clin. Invest., 1995 Mar;95(3):1018-25.	<input type="checkbox"/>
/C.A./	10	LEAF et al. "Do fish oils prevent restenosis after coronary angioplasty?" Circulation, 1994 Nov; 92(5):2247-57. (Massachusetts General Hospital, Charlestown 02129).	<input type="checkbox"/>
/C.A./	11	NUNES et al. "Combination of Vitamins C and E Alters the Response to Coronary Balloon Injury in the Pig." Arteriosclerosis, Thrombosis, and Vascular Biology, (1005), vol. 15, No. 1, pp. 156-165.	<input type="checkbox"/>
/C.A./	12	ONG et al. "Palm oil: a healthful and cost-effective dietary component." Food Nutr Bull. 2002 Mar;23(1):11-22. Review. PubMed PMID: 11975364.	<input type="checkbox"/>
/C.A./	13	RODES et al. "Prevention of restenosis after angioplasty in small coronary arteries with probucol." Circulation, 1998, Feb 10; 97(5):429-36.	<input type="checkbox"/>
/C.A./	14	SCHNEIDER et al. "Probucol Decreases Neointimal Formation in a Swine Model of Coronary Artery Balloon Injury." Basic Science Report, 88:628-637, 1993.	<input type="checkbox"/>
/C.A./	15	TARDIF et al. "Probucol and Multivitamins in the Prevention of Restenosis after Coronary Angioplasty." The New England Journal of Medicine, 337:365-372, 1997.	<input type="checkbox"/>
/C.A./	16	TARDIF "Insights into oxidative stress and atherosclerosis." Can J Cardiol. 2000 Jul;16 Suppl D:2D-4D. Review. PubMed PMID: 10932028.	<input type="checkbox"/>
/C.A./	17	TARDIF et al. "Prevention of restenosis with antioxidants: mechanisms and implications." Am J Cardiovasc Drugs. 2002;2(5):323-34. Review. PubMed PMID: 14727962.	<input type="checkbox"/>
/C.A./	18	TARDIF "Clinical results with AGI-1067: a novel antioxidant vascular protectant." Am J Cardiol. 2003 Feb 6;91 (3A):41A-49A. Review. PubMed PMID: 12645643.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595453
Filing Date	2006-04-28
First Named Inventor	James W. Larrick
Art Unit	1617
Examiner Name	Carlos A. Azpuru
Attorney Docket Number	1953233.00008

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Carlos Azpuru/	Date Considered	06/30/2011
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.